Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | AHR | P35869 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857632 | 0.86 | RAB9A (0.76) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL25857633 | 0.85 | RAB9A (0.74) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL25857631 | 0.82 | RAB9A (1.00) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL2268288 | 0.78 | RAB9A (0.66) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL6125865 | 0.77 | RAB9A (0.83) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL29069383 | 0.76 | MAPT (0.70) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL30767829 | 0.76 | MAPT (0.70) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL2274316 | 0.76 | RAB9A (0.62) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL12978020 | 0.75 | RAB9A (0.76) | RAB9AMAPTAHRMEN1KMT2A | |
| SCHEMBL8524625 | 0.74 | MAPT (0.67) | RAB9AMAPTAHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140255386-A1 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME | NORTH CAROLINA STATE UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013019469-A1 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME | THE WISTAR INSTITUTE (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20130023498-A1 | MicroRNA Modulators and Method for Identifying and Using the Same | The Wistar Institute and North Carolina State University | 2013-01-24 | — | — | US | disclosed |
| US-20130023498-A1 | MicroRNA Modulators and Method for Identifying and Using the Same | The Wistar Institute and North Carolina State University | 2013-01-24 | — | — | US | disclosed |
| US-20120010177-A1 | MicroRNA Modulators and Method for Identifying And Using The Same | The Wistar Institute / North Carolina State University (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010177-A1 | MicroRNA Modulators and Method for Identifying And Using The Same | The Wistar Institute / North Carolina State University (US) | 2012-01-12 | — | — | US | disclosed |
| US-20100196357-A1 | Microrna modulators and method for identifying and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | disclosed |
| US-20100196357-A1 | Microrna modulators and method for identifying and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196357-A1 | Microrna modulators and method for identifying and using the same | AGO2, RNASE1, TRDMT1 | RAB9A 2435/4885MAPT 4079/4885AHR 3877/4885 |
| US-20130023498-A1 | MicroRNA Modulators and Method for Identifying and Using the Same | AGO2, RNASE1, TRDMT1 | RAB9A 2435/4885MAPT 4079/4885AHR 3877/4885 |
| US-20120010177-A1 | MicroRNA Modulators and Method for Identifying And Using The Same | AGO2, RNASE1, TRDMT1 | RAB9A 2435/4885MAPT 4079/4885AHR 3877/4885 |
| US-20140255386-A1 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME | AGO2, RNASE1, TRDMT1 | RAB9A 2435/4885MAPT 4079/4885AHR 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.